Literature DB >> 21157201

Prognostic value of bone scintigraphy in cancer patients with osteonecrosis of the jaw.

Tim Van den Wyngaert1, Manon T Huizing, Eric Fossion, Jan B Vermorken.   

Abstract

PURPOSE OF THE REPORT: identifying imaging predictors of healing of osteonecrosis of the jaw (ONJ) in cancer patients may assist in better stratification of treatment strategies.
MATERIALS AND METHODS: patients with ONJ were followed prospectively and underwent bone scintigraphy, both planar and single-photon emission computed tomography (SPECT) imaging. End points were time to healing and the number of recurrences. Studied parameters included lesion visibility, pattern of uptake, and quantification of uptake relative to the unaffected side.
RESULTS: a total of 22 patients were recruited (3 men; 19 women) with a stage 1 ONJ lesion in 8, stage 2 in 9, and stage 3 ONJ in 5 patients. Median duration of follow-up was 12 months (range, 6-37). SPECT acquisitions proved superior over planar images in detecting ONJ lesions (P = 0.03). Quantification of tracer uptake in the ONJ lesion relative to the unaffected side showed increasing uptake with higher stages of ONJ: mean, 1.67 (95% confidence interval [CI], 1.17-2.18) in stage 1, 2.72 (95% CI, 2.24-3.20) in stage 2, and 4.62 (95% CI, 3.98-5.26) in stage 3. In addition, this relative ratio of uptake was found to be an independent predictor of ONJ healing (hazard ratio, 0.24; 95% CI, 0.07-0.82; P = 0.02). Neither ONJ stage nor relative ratio of uptake were predictors of the occurrence of ONJ relapses.
CONCLUSIONS: bone scintigraphy in patients with ONJ is feasible and SPECT acquisitions are preferred over planar images. Relative quantification of tracer uptake provides prognostic information independent of clinical stage that may assist in identifying patients with a poor prognosis.

Entities:  

Mesh:

Year:  2011        PMID: 21157201     DOI: 10.1097/RLU.0b013e3181feeb72

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  5 in total

1.  A comparative effectiveness pilot study of teriparatide for medication-related osteonecrosis of the jaw: daily versus weekly administration.

Authors:  Y Ohbayashi; A Iwasaki; F Nakai; T Mashiba; M Miyake
Journal:  Osteoporos Int       Date:  2019-11-25       Impact factor: 4.507

Review 2.  Highlights from 2017: impactful topics published in the Annals of Nuclear Medicine.

Authors:  Andrea Farolfi; Pietro Ghedini; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-09-28       Impact factor: 9.236

Review 3.  Imaging findings of bisphosphonate-related osteonecrosis of the jaws: a critical review of the quantitative studies.

Authors:  André Ferreira Leite; Fernanda Dos Santos Ogata; Nilce Santos de Melo; Paulo Tadeu de Souza Figueiredo
Journal:  Int J Dent       Date:  2014-06-11

4.  The EANM practice guidelines for bone scintigraphy.

Authors:  T Van den Wyngaert; K Strobel; W U Kampen; T Kuwert; W van der Bruggen; H K Mohan; G Gnanasegaran; R Delgado-Bolton; W A Weber; M Beheshti; W Langsteger; F Giammarile; F M Mottaghy; F Paycha
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-06-04       Impact factor: 9.236

Review 5.  Symposium: Imaging modalities for drug-related osteonecrosis of the jaw (1), role of imaging in drug-related osteonecrosis of the jaw: An up-to-date review (secondary publication).

Authors:  Makoto Tsuchimochi; Tohru Kurabayashi
Journal:  Jpn Dent Sci Rev       Date:  2019-01-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.